Marina Zhang
Marina Zhang is a health writer for The Epoch Times, based in New York. She mainly covers stories on COVID-19 and the healthcare system and has a bachelors in biomedicine from The University of Melbourne. Contact her at [email protected].
LATEST
FDA Issues Alert About Overdosing on Weight-Loss Drug After Some Take 5 to 20 Times the Intended Dose
Semaglutide is the active ingredient in popular injectable weight-loss drugs.
US Infant Mortality Increases for First Time in Decades: CDC Report
The most recent increase in infant mortality occurred in 2002.
Chronic Fatigue Syndrome ‘No More Likely’ After COVID Than Other Infections, CDC Study Finds
Researchers confirm myalgic encephalomyelitis/chronic fatigue syndrome can follow COVID-19 in up to 4 percent of those infected.
Blood Proteins Can Predict the Risk of Developing More Than 60 Diseases
Study authors found that examining blood proteins can better predict 52 diseases than current clinical tests.
COVID Social Distancing Linked to Newborn Mortality and Preterm Births, Study Finds
The authors believe that disrupted prenatal care contributed to newborn mortality.
Endometriosis Quadruples Ovarian Cancer Risk, Lifestyle Changes May Help
Moderate to severe endometriosis increases one’s risk of Type 1 ovarian cancer, according to a new study.
When More Informed, 20 Percent of Women in Their 40s Want to Delay Mammograms
In addition, a new study finds that most women who wanted to delay their mammograms were at low risk of breast cancer.
Popular Weight-Loss Drugs Not Linked to Higher Risks of Suicidality, but Small Caveat: Study
A new study in older patients suggests glucagon-like peptide-1 receptor agonists are not linked to higher suicidality risk.
Scientists Find a Cause of Lupus and a Way to Potentially Reverse It
Researchers believe targeting a chemical imbalance could more effectively treat lupus without systemic immunosuppression interventions.
Popular Weight-Loss, Diabetes Drug Linked to Sight-Threatening Condition; More Research Needed: Harvard Study
The study evaluated over 16,800 people referred to their clinic, of whom 555 took semaglutide to treat diabetes or obesity.
